Evidence map›Paper›PMID 31090281›Full record

SynthesisThe Journal of clinical psychiatry2019

Sleep-Associated Adverse Events During Methylphenidate Treatment of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis.

Stephen V Faraone, Michelle D Po, Marina Komolova, Samuele Cortese

Open access · greenAbstract readMeta-Analysis
In one paragraph

Synthesis in The Journal of clinical psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. The Role of GDNF and NSE in Attention-deficit/Hyperactivity Disorder: The Relationship with Sleep and Eating.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Dopamine Transporter andJournal of child and adolescent psychopharmacology · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. ADHD and sleep: recent advances and future directions.Current opinion in psychology · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Stephen V FaraoneSUNY Upstate Medical University, 750 East Adams St, Syracuse, NY 13210. sfaraone@childpsychresearch.org.
Michelle D PoHighland Therapeutics Inc, Toronto, Ontario, Canada.
Marina KomolovaHighland Therapeutics Inc, Toronto, Ontario, Canada.
Samuele CorteseCenter for Innovation in Mental Health, Academic Unit of Psychology; University of Southampton, Southampton, United Kingdom.
New York University · USSUNY Upstate Medical University · US

Funding

Longitudinal Family/Molecular Genetic Study to Validate Research Domain CriteriaR01MH101519 · NIMH · UPSTATE MEDICAL UNIVERSITY · PI FARAONE, STEPHEN V, GLATT, STEPHEN J · 2014 to 2018
$3.5M
3/7 Psychiatric Genomics Consortium: Finding actionable variationU01MH109536 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHARNEY, ALEXANDER W, HUCKINS, LAURA MARIANNE · 2016 to 2020
$2.7M
NIMH NIH HHS R01 MH101519NIMH NIH HHS U01 MH109536
6 · The paper itself

Abstract

objectiveSleep disturbances are a feature of attention-deficit/hyperactivity disorder (ADHD) and an adverse event (AE) of methylphenidate treatment. The authors sought to clarify methylphenidate-associated sleep problems and how studies are affected by confounding factors. DATA SOURCES: Published studies in English collected via online databases and unpublished data from www.clinicaltrials.gov and US Food and Drug Administration websites. Sources were searched from inception to August 2017. STUDY SELECTION: Included were blinded placebo-controlled studies of youth with ADHD conducted in naturalistic settings, leading to 35 studies yielding 75 observations of sleep-related AEs. These studies comprised 3,079 drug-exposed and 2,606 placebo-treated patients. DATA EXTRACTION: Two PhD-level reviewers reviewed each study for inclusion. Four PhD/PharmD-level reviewers extracted data in duplicate. Discrepancies were resolved by discussion or, if needed, by the senior author.

resultsIncreased pooled relative risks (RRs) were found for methylphenidate-associated sleep-related AEs for insomnia (general), initial insomnia, middle insomnia, combined insomnia, and sleep disorder. Several sample or study design features were significantly associated with the RR for sleep-related AEs and the methylphenidate formulation studied (P < .05). After correction for confounding variables, significant differences among drugs were found for initial insomnia, insomnia (general), and sleep disorder (P < .0001) as the other categories could not be tested due to insufficient studies. The findings also show that the RR and its interpretation are constrained by the placebo AE rate.

conclusionsSeveral types of insomnia and sleep problems are associated with methylphenidate treatment. Study design and sample features influence the RR statistic. By showing that the rate of placebo AEs impacts the RR, this study provides the field with a useful covariate for adjusting RR statistics.

Indexed as

AdolescentAttention Deficit Disorder with HyperactivityCase-Control StudiesChildControlled Clinical Trials as TopicHumansMethylphenidateSleep Wake DisordersMethylphenidate

Identifiers

PMID31090281
PMCPMC8074661
OpenAlexW2943624036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.